REG - Arecor Therapeutics - Arecor Appoints Chief Business Officer

Arecor TherapeuticsAnnouncement

05/04/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230405:nRSE3842Va&default-theme=true

RNS Number : 3842V  Arecor Therapeutics PLC  05 April 2023

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR APPOINTS DR. MANJIT RAHELU AS CHIEF BUSINESS OFFICER

 

-      Manjit is an accomplished strategic deal-maker bringing 25+ years
of scientific, commercial and financial experience across major global
pharmaceutical and biotechnology companies, specialising in product in and
out-licensing, commercial strategy, accelerating growth and M&A

-      Will play a key role in building and executing Arecor's ambitious
commercialisation and growth plans as pipeline of proprietary and partnered
products advances

 

Cambridge, UK, 5 April 2023: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
today announces the appointment of Dr. Manjit Rahelu as Chief Business
Officer, with immediate effect.

 

Sarah Howell, Chief Executive Officer at Arecor, said: "I am delighted to
welcome Manjit, who brings extensive experience nurturing the growth of
companies and driving deals to commercial success. We continue to make
significant progress across our in-house proprietary programmes, including our
clinical stage diabetes products as well as our pharma collaborations and,
with several important upcoming milestones, Manjit will play a key role in
meeting our strategic goal to build a significant self-sustaining
biopharmaceutical company."

 

Manjit is an accomplished strategic deal maker, with a strong scientific
background and over 25 years of technical, commercial and financial experience
across large and mid-sized pharmaceutical and biotechnology companies. He
brings extensive business development experience in product focused
clinical-stage licensing and M&A and, as a member of Arecor's Executive
team, will shape and oversee the Group's business and corporate development
strategy.

 

Dr. Manjit Rahelu, Chief Business Officer at Arecor, added: "Arecor has a
clear business strategy and has built both a valuable in-house portfolio of
proprietary product candidates and an impressive number of partnerships with
leading pharmaceutical and biotechnology companies - all powered by its novel
platform technology. I look forward to supporting the Group's growth towards
becoming a world leading and self-sustaining biopharmaceutical company."

 

Most recently, Manjit founded and served as Partner for Alcheme Advisors,
supporting early-stage businesses on a variety of business development,
strategy and optimisation projects. Prior to this, he held the role of Chief
Business Officer and Chief Operating Officer at Calchan, a UK biotechnology
company focussed on the development of novel molecules targeting pain and
inflammation. Here, he oversaw the shaping and implementing of the
organisation's strategy, processes, and infrastructure, as well as leading
business development efforts.

 

Manjit also served as Vice President Business Development at Convergence
Pharmaceuticals, where, as a member of the leadership team, he helped to shape
the company's growth strategy, with primary responsibility for leading
business development initiatives to commercialise its chronic pain assets. He
played a pivotal role in cementing the sale of Convergence to Biogen for £675
million in 2015.  Earlier in his career, he held positions with increasing
responsibilities at a variety of life science companies including Sanofi,
Allergy Therapeutics and UCB.

 

Manjit holds a BSc Hons in Biochemistry from the University of Sussex and a
PhD in Immunology from the University of Birmingham.

 

 

-ENDS-

 

 

For more information, please contact:

 Arecor Therapeutics plc                         www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer        Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Susan Lowther, Chief Financial Officer          Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Mo Noonan, Communications                       Tel: +44 (0) 7876 444977

                                                 Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)  Tel: +44 (0) 20 7886 2500

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Lindsey Neville     Tel: +44 (0) 20 3709 5700

                                                 Email: arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio. For further details
please see our website, www.arecor.com (http://www.arecor.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAXLLEEDDEFA